influenza

Anti-Influenza agent 4 is a potent and selective inhibitor of the influenza virus, effectively inhibiting the A Parma and A Roma strains with EC50s of 62 nM and 150 nM, respectively.

(-)-Arctigenin ((-)-Arctigenin) is found in burdock. (-)-Arctigenin is isolated from Cnicus benedictus, Forsythia viridissima, Arctium lappa, Ipomoea cairica and others (CCD). Arctigenin is a lignan found in certain plants of the Asteraceae, including the Greater burdock (Arctium lappa) and Saussurea heteromalla. It has shown antiviral and anticancer effects. It is the aglycone of arctiin.

Influenza HA 126-138 acetate is a influenza virus hemagglutinin (HA) peptide acetate comprising amino acids 126-138. Influenza HA 126-138 acetate induces thymic and peripheral T-cell apoptosis.

Influenza HA (126-138) is a peptide derived from the hemagglutinin (HA) protein of the influenza virus, consisting of amino acids 126-138, and has the ability to induce apoptosis in both thymic and peripheral T-cells.

Influenza A virus-IN-8 (S5), a macrocyclic peptide, exhibits no cytotoxicity and acts as a potent inhibitor of Influenza A Virus (IAV), demonstrating significant protease stability, with IC50 values of 6.7 nM for H1 and 6.6 nM for H5 variants. It has a high affinity for H1 variants, binding to a conserved region in the HA stem with a dissociation constant (Kd) of 1.0 nM [1].

Influenza virus-IN-3 (compound 9) is a potent inhibitor of selective influenza viruses, with IC50 values of 0.88 μM for H5N1, 0.10 μM for H5N2, 5.5 μM for H5N6, and 0.51 μM for H5N8. Influenza virus-IN-3 exhibits antiviral and NA (neuraminidase) inhibitory effects with low cytotoxicity (CC50 > 200 μM).

Influenza virus-IN-7 (Example 16) is an orally active cap-dependent endonuclease inhibitor used in influenza viral infectious disease research [1].

Influenza Matrix Protein (61-72) is a peptide derived from the matrix protein of influenza viruses, encompassing amino acids 61-72, and has the ability to elicit a CD4+ T-cell response.

Influenza Hemagglutinin is an HLA-DRB 0101-restricted epitope from influenza hemagglutinin (307-319).

PA (224-233), Influenza is a 10-aa peptide fragment of the polymerase 2 protein in the Influenza A virus.

Influenza A virus fragment has the RNA sequence of Leu-Lys-Phe-Ala-Phe-Ser-Met-Met.

CEF8, Influenza Virus NP (383-391), is an influenza A virus nucleoprotein containing residues 383 to 391, and it is the most important HLA-B*2705-restricted epitope in the nucleoprotein of influenza A viruses, associated with escape from cytotoxic T lymphocytes-mediated immunity. [HLA-B*3501 restricted influenza virus nucleoprotein epitope (383-391).]

Influenza HA (307-319) acetate is the 307-319 amino acid fragment of the influenza virus hemagglutinin (HA) protein, an HLA-DRB1 0101-restricted epitope polypeptide with the sequence PKYVKQNTLKLAT, which can be used for the study of influenza virus immunogenicity as well as for the development of vaccines and diagnostic reagents against influenza virus.

Influenza virus-IN-8 (compound A4), an inhibitor of the influenza virus (Influenza Virus), functions by inducing aggregation of the viral nucleoprotein (NP) and blocking its accumulation in the nucleus. This compound exhibits broad-spectrum anti-influenza properties, effectively inhibiting the replication and transcription of influenza A virus. Additionally, Influenza virus-IN-8 is effective against Oseltamivir-resistant H1N1 pdm09 strains [1].

Influenza virus-IN-2 (compound 19) is a potent inhibitor of influenza A virus with anti-influenza activities, exhibiting a CC50 of 150.85 μM and an EC50 of 2.58 μM. Concentration-dependently, Influenza virus-IN-2 inhibits the PAN endonuclease with an EC50 of 489.39 nM [1].

Influenza A virus-IN-7 (compound 16r) is a potent, orally active inhibitor of influenza A virus with an IC50 of 3.43 μM and a CC50 greater than 100 μM. This anti-IAV agent exhibits low cytotoxicity and effectively inhibits viral RNA transcription and replication.

Influenza A virus-IN-5 (Compound 16e) is a highly potent and orally active agent against influenza A virus (IAV), with an IC50 of 1.29 μM. It effectively inhibits viral RNA transcription and replication while maintaining acceptable levels of cytotoxicity [1].

Anti-Influenza agent 3 (compound 11h) is a potent anti-influenza agent with low cytotoxicity for MDCK epithelial cells, inhibiting the M2 WT and S31N ion channel conductivity. It has an EC50 value of 3.29 μM for A HK 68 (H3N2, M2-WT) and 2.45 μM for A WSN 33 (H1N1, M2-S31N) strain [1].

Influenza A virus-IN-15 (Compound 9b), a quinoline derivative, is a broad-spectrum anti-influenza inhibitor with an IC50 range of 0.88-6.33 μM and demonstrates acceptable cytotoxicity. It inhibits the transcription and replication of viral RNA, making it suitable for research on Influenza A virus (IAV).

This peptide is a H2-Db-restricted epitope from Influenza nucleoprotein (147-155).

CEF1, Influenza Matrix Protein M1 (58-66), is an epitope derived from the matrix protein of the influenza A virus. GILGFVFTL is an HLA-A2-restricted epitope from this matrix M1 protein.

Influenza A NP (383-391) (HLA-B27) is a peptide sequence derived from tetanus toxin. It serves as an epitope for CD4+ T helper cells, exhibiting broad immunogenic properties that enhance the response of CD8+ cytotoxic T lymphocytes (CTL). Additionally, this compound is utilized in the research of breast cancer.

Influenza A virus-IN-4 (compound 23b), a derivative of Oseltamivir, is a highly effective neuraminidase inhibitor that exerts potent inhibitory effects on influenza viruses [1].

Anti-Influenza agent 5 (Compound IIB-2), a chalcone-like derivative, serves as an influenza nuclear export inhibitor, effectively inhibiting oseltamivir-resistant strains and hindering viral proliferation by obstructing the export of influenza virus nucleoprotein [1].